ITGB1 and breast neoplasm: While several studies have explored the potential of ablating ITGB1 with genetic approaches, demonstrating reduced breast tumour growth and metastasis in xenograft and genetically engineered mouse models14,54,55, targeting integrin heterodimers, has so far failed to show efficacy in a cancer setting13,56.